NASDAQ:RLAY - Relay Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $57.40
  • Forecasted Upside: 77.93 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$32.26
▼ -0.37 (-1.13%)
1 month | 3 months | 12 months
Get New Relay Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RLAY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RLAY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$57.40
▲ +77.93% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Relay Therapeutics in the last 3 months. The average price target is $57.40, with a high forecast of $66.00 and a low forecast of $48.00. The average price target represents a 77.93% upside from the last price of $32.26.
Buy
The current consensus among 6 contributing investment analysts is to buy stock in Relay Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/22/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/20/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/21/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2021JMP SecuritiesBoost Price TargetAverage ➝ Outperform$50.00 ➝ $66.00High
i
1/29/2021JPMorgan Chase & Co.Boost Price TargetNeutral$36.00 ➝ $52.00High
i
12/15/2020HC WainwrightReiterated RatingBuy$54.00 ➝ $57.00Medium
i
Rating by R. Burns at HC Wainwright
12/8/2020JMP SecuritiesInitiated CoverageOutperform$66.00High
i
11/5/2020HC WainwrightInitiated CoverageBuy$54.00High
i
Rating by R. Burns at HC Wainwright
8/10/2020GuggenheimInitiated CoverageBuy$48.00Low
i
8/10/2020CowenInitiated CoverageOutperformLow
i
8/10/2020JPMorgan Chase & Co.Initiated CoverageNeutral$36.00Low
i
8/10/2020The Goldman Sachs GroupInitiated CoverageBuy$64.00Low
i
(Data available from 4/21/2016 forward)
Relay Therapeutics logo
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company's lead product candidates include RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $32.26
$31.50
$32.99

50 Day Range

MA: $36.27
$31.97
$40.27

52 Week Range

Now: $32.26
$30.72
$64.37

Volume

214,572 shs

Average Volume

764,398 shs

Market Capitalization

$2.92 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Relay Therapeutics?

The following Wall Street analysts have issued research reports on Relay Therapeutics in the last twelve months: Cowen Inc, Guggenheim, HC Wainwright, JMP Securities, JPMorgan Chase & Co., The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for RLAY.

What is the current price target for Relay Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Relay Therapeutics in the last year. Their average twelve-month price target is $57.40, suggesting a possible upside of 77.9%. JMP Securities has the highest price target set, predicting RLAY will reach $66.00 in the next twelve months. Guggenheim has the lowest price target set, forecasting a price of $48.00 for Relay Therapeutics in the next year.
View the latest price targets for RLAY.

What is the current consensus analyst rating for Relay Therapeutics?

Relay Therapeutics currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RLAY will outperform the market and that investors should add to their positions of Relay Therapeutics.
View the latest ratings for RLAY.

What other companies compete with Relay Therapeutics?

How do I contact Relay Therapeutics' investor relations team?

Relay Therapeutics' physical mailing address is 399 BINNEY STREET 2ND FLOOR, CAMBRIDGE MA, 02139. The company's listed phone number is 617-370-8837 and its investor relations email address is [email protected] The official website for Relay Therapeutics is www.relaytx.com.